Literature DB >> 24407773

A case of vasospastic angina in which the ergonovine provocation test with intracoronary isosorbide dinitrate and nicorandil was effective in the diagnosis of microvascular spasm.

Takahiko Kiyooka1, Yoshinori Kobayashi, Yuji Ikari.   

Abstract

A 60-year-old man was admitted with early morning angina while at rest. Coronary angiogram revealed no organic lesions; therefore, a spasm provocation test with ergonovine was performed. Administration of intracoronary ergonovine induced total occlusion of the right coronary artery. The induced total occlusion improved but coronary flow velocity remained severely reduced and chest discomfort with ST-T changes in ECG remained in spite of repeated administration of isosorbide dinitrate (ISDN). Intracoronary administration of nicorandil following ISDN alleviated the chest discomfort, normalized the ST-T change in ECG, and improved the coronary flow. This suggested that microvascular spasm and the epicardial spasm were not relieved by ISDN but by nicorandil. Intracoronary nicorandil injection following ISDN administration may be useful for the diagnosis of microvascular spasm in the ergonovine provocation test.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24407773     DOI: 10.1007/s12928-013-0237-1

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  3 in total

Review 1.  Overview of Microvascular Angina Pectoris and Discussion of Traditional Chinese Medicine Intervention.

Authors:  Linghua Yu; Xiaoyan Lu; Chenxi Xu; Tong Li; Yanling Wang; Anxiang Liu; Yubi Wang; Li Chen; Huangyu Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-05       Impact factor: 2.629

2.  Association of uric acid levels with cardiac syndrome X: A meta-analysis.

Authors:  Wu Zu; Chen-Chen Li; Xin-Yu Wang; Qiu-Shi Li; Bing Liu
Journal:  Front Physiol       Date:  2022-10-03       Impact factor: 4.755

Review 3.  Vasodilator Therapy: Nitrates and Nicorandil.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Cardiovasc Drugs Ther       Date:  2016-08       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.